enasidenib in midh relapsed and refractory aml
Published 7 years ago • 551 plays • Length 4:02Download video MP4
Download video MP3
Similar videos
-
4:05
enasidenib in relapsed/refractory mutant idh2 aml
-
4:42
ivosidenib or enasidenib in mutant idh1 or idh2 relapsed/refractory acute myeloid leukemia (r/r aml)
-
1:48
idh1 inhibitor ivosidenib for the treatment of relapsed/ refractory aml
-
8:55
aml: identifying practical concerns with enasidenib
-
4:20
enasidenib’s role in idh-mutant acute myeloid leukemia
-
3:05
rationale for enasidenib in aml
-
1:24
phase i results for enasidenib in aml
-
3:16
is enasidenib plus azacitidine better than with azacitidine alone for aml patients?
-
5:29
case 3: idh inhibitors for the treatment of aml
-
59:54
combination therapies for relapsed or refractory aml
-
0:50
combining azacitadine/enasidenib to enhance the treatment of newly diagnosed idh2-mutant aml
-
0:58
dr. al-kali on fda approval of enasidenib in aml
-
5:52
eytan m. stein, md: enasidenib shows "encouraging" efficacy in idh2-mutated aml
-
2:01
phase ii trial of enasidenib in idh2-mutant mds
-
8:26
enasidenib in mutant-idh2 r/r aml: results of a phase 1 dose-escalation and expansion study
-
1:51
which r/r aml subgroups would benefit from enasidenib treatment?
-
2:52
ivosidenib or enasidenib with chemotherapy for aml produces deep remissions
-
0:32
ivosidenib for patients with relapsed or refractory aml
-
4:24
the efficacy and safety of enasidenib plus azacitidine versus azacitidine monotherapy in mutant-...